swampboots, that was the pathway that both TRIL and FTSV developed inhibitors for so that macrophages could be activated. Not sure whether it is better or commercially more advantageous to take out macrophages from each cancer patient to engineer them or use off the shelf inhibitors ala TRIL and FTSV. I am waiting to see if/when some combination studies are used, such as T-cell and macrophages therapies either simultaneously or sequentially.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.